Search company, investor...

Xanthus Pharmaceuticals

xanthus.com

Founded Year

2001

Stage

Acquired | Acquired

Total Raised

$63.8M

Valuation

$0000 

About Xanthus Pharmaceuticals

Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel, clinical-stage, small-molecule therapeutic candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialisation. The Company is applying its expertise to advance its current pipeline to address significant unmet medical need in oncology and autoimmune diseases. Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec.

Headquarters Location

300 Technology Square

Cambridge, Massachusetts, 02139,

United States

617-225-0522

Missing: Xanthus Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Xanthus Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Xanthus Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Xanthus Pharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Xanthus Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Xanthus Pharmaceuticals founded?

    Xanthus Pharmaceuticals was founded in 2001.

  • Where is Xanthus Pharmaceuticals's headquarters?

    Xanthus Pharmaceuticals's headquarters is located at 300 Technology Square, Cambridge.

  • What is Xanthus Pharmaceuticals's latest funding round?

    Xanthus Pharmaceuticals's latest funding round is Acquired.

  • How much did Xanthus Pharmaceuticals raise?

    Xanthus Pharmaceuticals raised a total of $63.8M.

  • Who are the investors of Xanthus Pharmaceuticals?

    Investors of Xanthus Pharmaceuticals include Sarossa Capital, Tekla Capital Management, CDP Capital, Still River Funds, CDIB BioScience Venture Management and 9 more.

  • Who are Xanthus Pharmaceuticals's competitors?

    Competitors of Xanthus Pharmaceuticals include Arena Pharmaceuticals, Evotec SE, Constellation Pharmaceuticals, Kiadis Pharma, Actinobac Biomed, Acetylon Pharmaceuticals, Diffusion Pharmaceuticals, Catabasis Pharmaceuticals, Tolera Therapeutics, Verva Pharmaceuticals and 13 more.

Compare Xanthus Pharmaceuticals to Competitors

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

U
United Biomedical

United Biomedical operates as a biopharmaceutical company. The Company develops immunotherapeutics and vaccines for chronic and infectious diseases.

J
JadoLabs

JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

M
MuriGen

MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.

A
AnaMar Medical

AnaMar Medical is a company in the field of cartilage biology and associated joint diseases. The company has an project portfolio with five drugs and one biomarker in development and two biomarkers on the market.

S
SBIO Pte

SBIO is focused on the discovery and development of small molecule oncology drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.